Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AarF domain containing kinase 5 (ADCK5)
- Target
- ADCK5
- Molecular classification
- Enzyme, Protein serine/threonine kinase (putative), Membrane protein, Mitochondrial protein
01
Overview
AarF domain containing kinase 5 (ADCK5) is a member of the atypical aarF domain-containing kinase family located on human chromosome 8q24.3. It is predicted to function as a serine/threonine kinase and is localized to mitochondria. ADCK5 participates in the regulation of mitochondrial integrity, cellular metabolism, and maintains cellular homeostasis, possibly affecting mitochondrial energy production and cell signaling. Emerging research implicates ADCK5 in the invasion and migration of lung cancer cells, primarily through phosphorylation of the transcription factor SOX9 and upregulation of oncogenic PTTG1. While its precise biological functions and substrates remain incompletely defined, ADCK5 has disease associations spanning cancer and metabolic syndromes, making it a potential but underexplored therapeutic target.
- Other names
- ADCK5Uncharacterized aarF domain-containing protein kinase 5FLJ35454Putative aarF domain-containing protein kinase 5
02
Mechanism of action
No approved drugs; hypothetically, small molecule inhibitors could affect ADCK5 kinase function or its protein-protein interactions involved in mitochondrial maintenance or cancer cell invasion
03
Biological functions
Predicted protein serine/threonine kinase activityMitochondrial maintenance and homeostasisRegulation of cell migration and invasionSignal transductionCell cycle regulationCellular differentiationCell survivalEnergy production and metabolism (general family role)
04
Disease associations
Cancer (particularly lung, pancreatic, prostate)AsthmaAbdominal obesity-metabolic syndrome 1 (database link but not functionally proven)
05
Safety considerations
Potential concerns include off-target inhibition of kinases affecting mitochondrial homeostasis, which may induce metabolic dysfunction or unanticipated toxicity in tissues with high ADCK5 expressionSafety profiles are currently unclear due to lack of drug development.
06
Biomarkers
ADCK5 overexpression may serve as a biomarker for lung cancer progression and invasiveness, via the ADCK5-SOX9-PTTG1 pathwayIts expression is noted in other tissue types but specific biomarker status is preliminary.
Beyond the preview
Go deeper on AarF domain containing kinase 5 (ADCK5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AarF domain containing kinase 5 (ADCK5).